期刊文献+

软肝化坚颗粒对肝纤维化模型C57小鼠肝脏PDGF-B表达的影响 被引量:1

Effect of Ruangan Huajian granule on hepatic expression of PDGF-B in C57 mice with experimental hepatic fibrosis
下载PDF
导出
摘要 目的观察软肝化坚颗粒对肝纤维化模型C57小鼠肝组织血小板衍生生长因子-B(PDGF-B)表达的影响。方法 50只C57小鼠被随机分为5组,每组10只。采用四氯化碳腹腔注射制造小鼠肝纤维化模型,通过免疫组织化学染色方法检测各实验组肝组织中PDGF-B的表达,对不同剂量软肝化坚颗粒进行实验对比,同时进行肝组织炎症评分(G)和纤维化评分(S)。结果各实验组肝组织PDGF-B表达、炎症和纤维化评分与正常对照组比较,差异均具有统计学意义(P<0.05);模型对照组肝组织PDGF-B表达、炎症和纤维化评分明显高于软肝化坚颗粒低剂量组、高剂量组和秋水仙碱组,差异均具有统计学意义(P<0.05);软肝化坚颗粒低剂量组、高剂量组和秋水仙碱组肝组织PDGF-B表达、炎症和纤维化评分差异无统计学意义(P>0.05)。结论软肝化坚颗粒可能通过降低C57小鼠肝组织PDGF-B的表达,进而减轻肝纤维化程度和肝组织损伤。 Objective To observe the effect of Ruangan Huajian granule on hepatic expression of PDGF-B in C57 mice with experimental hepatic fibrosis.Methods Fifty C57 mice were randomly divided into five groups(10 mice in each group),i.e.normal control group,control model group,low-dose Ruangan Huajian granule model group,high-dose Ruangan Huajian granule model group and colchicine model group.C57 mice with experimental hepatic fibrosis were induced by intraperitoneal injection of 10% CCl4.The expression of PDGF-B in liver tissue of mice was observed by immune histochemical technique.Compare the expression of PDGF-B in different Ruangan Huajian granule dosage group with other experimental groups.The scores of inflammation grade(G) and fibrosis stage(S) in liver tissue were also analyzed.Results The expression of PDGF-B and the scores of G and S in model groups were significantly higher than those in normal control group(P0.05),and that of model control group were significantly higher than Ruangan Huajian granule low-dose model group,Ruangan Huajian granule high-dose model group and colchicine model group(P0.05).There was no significant difference among Ruangan Huajian granule low-dose model group,Ruangan Huajian granule high-dose model group and colchicine model group(P0.05).Conclusion Ruangan Huajian granule may alleviate the degree of liver inflammation and fibrosis through reducing hepatic expression of PDGF-B in C57 mice with experimental hepatic fibrosis.
出处 《临床肝胆病杂志》 CAS 2011年第10期1047-1050,共4页 Journal of Clinical Hepatology
基金 河北省中医药管理局科学技术研究计划基金项目(2008055) 中国肝炎防治基金会王宝恩肝纤维化研究基金项目(20080013)
关键词 肝硬化 血小板源性生长因子 疾病模型 动物 软肝化坚颗粒 liver cirrhosis platelet-derived growth factor disease models animal Ruangan Huajian granule
  • 相关文献

参考文献5

二级参考文献48

  • 1周玉琴,李殿滨,傅蓉蓉.益气活血、软坚化瘀法治疗肝纤维化临床观察[J].上海中医药杂志,2005,39(6):26-27. 被引量:6
  • 2黄丽雯,程良斌.中药以肝星状细胞为靶点的抗肝纤维化研究进展[J].中西医结合肝病杂志,2007,17(3):191-192. 被引量:5
  • 3Siegmund SV,Schwabe RF.Endocannabinoids and liver disease.II.Endocannabinoids in the pathogenesis and treatment of liver fibrosis[J].Am J Physiol Gastrointest Liver Physiol,2008,294(2):G357-G362.
  • 4Hosui A,Kimura A,Yamaji D,et al.Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation[J].J Exp Med,2009,206(4):819-831.
  • 5Scheuer.PJ.Classification of chronic viral hepatitis:a need for reassessment[J].J Hepatol,1991,13(3):372-374.
  • 6Siegmund SV,Schwabe RF,et al.Endocannabinoids and Liver Disease.II.Endocannabinoids in the pathogenesis and treatment of liver fibrosis[J].Am J Physiol Gastrointest Liver Physiol,2008,294:G357-G362.
  • 7Mallat A, Lotersztajn S. Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest, 2006, 29(3 Suppl): 58-65.
  • 8Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.Nat Med, 2006, 12: 671-676.
  • 9Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med, 2001, 7: 827-832.
  • 10Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J, 2005, 7: E625-654.

共引文献77

同被引文献9

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部